We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Comparison of the Adjunctive Administration of Raloxifene and Isradipine in Reducing Cognitive Deficits of Patients with Schizophrenia.
- Authors
Vahdani, B.; Armani kian, A.; Esmaeilzadeh, A.; Zenoozian, S.; Mazloomzadeh, S.
- Abstract
Introduction: Cognitive impairments are from among the most important features of schizophrenia that lead to severe social and functional disabilities. Objective: The current study was conducted aimed at investigating the effects of Raloxifene as a selective estrogen modulator and Isradipine as a voltage gated L type calcium channel blocker on reducing cognitive deficits in schizophrenic patients. Methods: In this study, some double blind randomized, parallel, placebo controlled clinical trials were designed and performed. 60 patients with schizophrenia were categorized in 3 specific groups. Each group received Isradipine capsule 5 mg and Raloxifene tablet 60 mg twice a day, or placebo for 6 consequent weeks, with the capsules of the same shape, along with treatment with conventional antipsychotics. The initial and final lab tests, ECG, and cognitive tests in specific domains, including the attention, processing speed, executive function and verbal memory were assessed. Results: The findings exhibited a significant correlation between the adjunctive treatment with Raloxifene and the verbal memory deficit enhancement (P value= 0.002). Moreover, treatment with Isradipine indicated a significant improvement compared with placebo in verbal memory (P value= 0.005) as well as the attention dysfunction in some varieties of the Stroop test. However, in this study, no enhancement was observed either in the processing speed or in the executive function deficits. Conclusion: Improving the neurocognitive physiopathologic aspect of schizophrenia is a current challenge in identifying the pathway to developing goal-directed clinical interventions in practice. This study provides the evidence that Isradipine can be used as a novel therapy recommended to improve the cognitive impairment of schizophrenic patients who seem to follow a different way in their whole life, yet further investigation is required.
- Subjects
RALOXIFENE; COGNITION disorders; PEOPLE with schizophrenia; VERBAL memory; STROOP effect; EXPERIMENTAL design
- Publication
Iranian Journal of Psychiatry & Behavioral Sciences / Progress in Psychiatry & Behavioral Sciences, 2018, p168
- ISSN
1735-8639
- Publication type
Article